BIOSYNEX SA strengthens its governance with new appointments

On May 13, 2024, BIOSYNEX, a leading French health diagnostics laboratory, announced key changes in its governance. Oren Bitton has been promoted to the position of Deputy Managing Director of the group, after having successfully led the Pharma Business Unit since 2022. This promotion is part of BIOSYNEX's TRANSFORM 2025 plan aimed at stimulating growth and returning to profitability.

The BIOSYNEX board of directors also proposed the appointment of two new directors, to be approved at the General Meeting of shareholders scheduled for June 7. Brigitte Geny is envisaged as an independent Director, bringing her expertise in audit and finance, while Diane Abensur is approached to join the board in the wake of her experiences in entrepreneurship and medical technology.

These appointments strengthen the expertise of the BIOSYNEX board, particularly in the fields of health and medicine of the future, including aspects linked to environmental and social governance (ESG).